AstraZeneca Places $420M Bet On Mass. Biotech Startup
Battered by patent expirations and pipeline failures, AstraZeneca PLC on Thursday outlined part of its plan to bounce back by betting as much as $420 million on unproven biologic therapies developed...To view the full article, register now.
Already a subscriber? Click here to view full article